• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update

home / publications / supplement / biosimilars-for-immune-mediated-inflammatory-diseases-2022-update
Site Logo

Participating Faculty: Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update

November 1st 2022
Article
Site Logo

Introduction to Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update

Sonia T. Oskouei, PharmD
November 1st 2022
Article
Site Logo

Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence

Vibeke Strand, MD;Colby Evans, MD;Allan Gibofsky, MD, JD
November 1st 2022
Article
Site Logo

Biosimilar medicines: what are they and how are they used?

Vibeke Strand, MD;Colby Evans, MD;Allan Gibofsky, MD, JD
November 1st 2022
Article

Plain Language Summary

Site Logo

Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

Allan Gibofsky, MD, JD;Colby Evans, MD;Vibeke Strand, MD
November 1st 2022
Article
Site Logo

What do patients and health care providers still need to know about biosimilar medicines?

Allan Gibofsky, MD, JD;Colby Evans, MD;Vibeke Strand, MD
November 1st 2022
Article

Plain Language Summary

Site Logo

eAppendix: Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

Allan Gibofsky, MD, JD;Colby Evans, MD;Vibeke Strand, MD
November 1st 2022
Article
Site Logo

Biosimilars for Immune-Mediated Inflammatory Diseases – A Managed Care Perspective

Colby Evans, MD;Allan Gibofsky, MD, JD;Vibeke Strand, MD
November 1st 2022
Article
Site Logo

What are the current challenges to wider biosimilar use in the United States?

Colby Evans, MD;Allan Gibofsky, MD, JD;Vibeke Strand, MD
November 1st 2022
Article

Plain Language Summary

© 2024 MJH Life Sciences
AJMC®
All rights reserved.